Lung metastases from intraductal papillary neoplasm of the bile duct: a case report

Rika Fujino 1, Yoshihito Masuoka 1*, Taro Mashiko 1, Akira Nakano 1, Kenichi Hirabayashi 2 and Toshio Nakagohri 1

Abstract

Background: Intraductal papillary neoplasm of the bile duct (IPNB) is considered a pre-cancerous biliary lesion and/or an early cancer lesion, although its classification remains unclear. The 2019 revised edition of the World Health Organization Classification of Tumors of the Digestive System proposed type 1 and type 2 as new classification categories, and meta-analyses and/or multi-center cohort studies are beginning to be reported. However, treatment for IPNB recurrence and metastasis remains unclear.

Case presentation: A 60-year-old man who was referred to our hospital after a suspected liver tumor was diagnosed using abdominal ultrasonography. Imaging findings revealed an irregularly shaped tumor in segment 5 (S5) of the liver (size 20 mm). The S5 lesion was suspected as IPNB, and segmentectomy was performed. The pathological findings revealed invasive carcinoma derived from IPNB, and immunohistochemistry revealed positive expression of MUC1, MUC5AC, and MUC6, but negative expression of CDX2 and MUC2. At 9 months after the surgery, computed tomography revealed a tumor in the right bile duct, which was diagnosed as liver recurrence of IPNB, and right hepatectomy was performed. The histopathological findings were the same as for the first resected specimen (i.e., IPNB). At 45 months after the second surgery, computed tomography revealed nodules in both lungs, which were diagnosed as lung metastases from IPNB and resected in two separate procedures. The pathological findings were metastatic carcinoma from IPNB for both lung lesions. The patient is currently alive and undergoing adjuvant chemotherapy (S-1), which was initiated 64 months after the first resection and 12 months after resection of the lung metastases.

Conclusion: We encountered a rare case of lung metastases from IPNB, which were diagnosed immunohistologically. Because IPNB is generally a slow-growing tumor, resection may be feasible for IPNB recurrence and/or metastasis, which may be detected during long-term follow-up. Thus, even if resection is performed for primary IPNB, additional surgical treatment may be feasible in this setting.

Keywords: Intraductal papillary neoplasm of the bile duct, IPNB, Recurrence, Re-resection, Lung metastasis, Surgery
as intraductal papillary neoplasm with associated invasive carcinoma. IPNB is classified as type 1 (intrahepatic) or type 2 (extrahepatic), which was suggested by a Japanese–Korean study group [4] and adopted by the WHO in 2019 [3]. Although IPNB is a rare tumor, it is thought to have regional variations in its incidence. For example, in eastern Asia, IPNB accounts for 10–38% of bile duct tumors, and the intestinal/gastric types are the most common [3]. There is a minimal risk of recurrence and death in cases involving low-grade dysplasia, although cholangiocarcinoma derived from IPNB is associated with a 5-year recurrence rate of 47.0% and a 5-year overall survival rate of 68.8% [3]. You et al. reported 74 cases with invasive IPNB [5] and noted that local recurrence was the most common first recurrence site, with distal metastasis potentially involving the liver, peritoneum, and retroperitoneal lymph nodes. However, we are only aware of two previous cases involving lung metastasis from IPNB, which were reported by Höhn et al. in a single-center survey [6] and another case report [7]. Thus, because it is unclear what treatment is appropriate for IPNB recurrence and/or metastasis, we report what we believe is the third case of lung metastasis from IPNB.

**Case presentation**

A 60-year-old man was referred to our hospital after a suspected liver tumor was identified using abdominal ultrasonography. The patient did not exhibit any symptoms at the referral, although he was receiving medication to manage hypertension and hyperlipemia. Laboratory test results revealed normal findings for carcinoembryonic antigen (CEA, 10.7 ng/mL) level, cancer antigen 19-9 (CA19-9, 33.1 U/mL) level, and protein induced by vitamin K absence or antagonist-II (26 mAU/mL) level. Abdominal ultrasonography showed an irregularly shaped tumor in segment 5 (S5) of the liver, with a hyperechoic core (size 20 mm) in the intrahepatic area and peripheral to the hypoechoic area. The hyperechoic area was even more intense at the posterior aspect of the tumor (Fig. 1a). Abdominal dynamic computed tomography (CT) revealed an irregularly shaped and enhanced tumor in S5 of the liver during the arterial phase (Fig. 1b). Endoscopic retrograde cholangiography (ERC) revealed a filling defect from the origin of the right area to the periphery and severe dilation of the S5 branch of the bile duct (Fig. 1c). ERC showed a mucus discharge from the ampulla of Vater; however, we were not able to confirm adenocarcinoma via brushing cytology from the bile duct, doubting the...
presence of a mucus-producing tumor (especially IPNB). Therefore, we decided on surgery, performing segmentectomy for the S5 lesion. We decided to perform segmentectomy because the result of the rapid diagnosis made based on the bile duct stump during surgery was negative. The resected liver showed the papillary and nodular tumor in the dilatation of the intrahepatic bile duct (Fig. 2a). Microscopically, complex papillary or tubular proliferation of atypical columnar or cuboidal cells with focal fine vascular stroma was observed in the dilated intrahepatic bile ducts (Fig. 2b). Most of the tumor was composed of high-grade atypical cells with enlarged nuclei, whereas low-grade dysplasia components were focally observed (Fig. 2c). The tumor focally invaded into the stroma of the portal area in mucinous trabecular or tubular fashion but without invasion to the liver parenchyma (Fig. 2d). Immunohistochemically, MUC1 and MUC5AC were diffusely positive, and MUC6 was focally positive; however, MUC2 was negative (Fig. 2e–h). From these histological features, we diagnosed as IPNB associated with invasion (pT1aN0M0 stage IA, the 8th edition of UICC). From the tumor, mainly composed of high-grade atypical cells with complex papillary or tubular structure, and immunohistochemical pattern of MUC expressions (MUC1+/MUC2-/MUC5AC+/MUC6+), the subtype was considered as pancreatobiliary. In addition, because the tumor was located in the intrahepatic bile ducts, and histological features were similar to pancreatic intraductal papillary mucinous neoplasm, we considered it IPNB type 1. There was no lymph node or distant metastasis. Adjuvant chemotherapy was not provided because we observed no histopathological evidence of residual tumor.

The patient remained in good condition until CT revealed recurrence in the right hepatic duct at 9 months after the surgery (Fig. 3a). ERC revealed a filling defect in the origin of the right bile duct, and intraductal Figure 2 Macroscopic and pathological findings from the first resection. a The papillary and nodular tumor in the dilatation of intrahepatic bile duct (white arrow). b Complex papillary or tubular proliferation of atypical columnar or cuboidal cells with focal fine vascular stroma was observed in the dilated intrahepatic bile ducts. c Most of the tumor was composed of high-grade atypical cells that had enlarged nuclei, whereas low-grade dysplasia components were focally observed. d Tumor focally invaded into the stroma of portal area with mucinous trabecular or tubular fashion, although there was no invasion to the liver parenchyma. Immunohistochemistry findings are shown for e MUC1, f MUC2, g MUC5AC, and h MUC6
ultrasonography (IDUS) revealed a papillary tumor (Fig. 3b, c). We diagnosed the patient with intrahepatic recurrence of IPNB and performed right hepatectomy. Macroscopically, the papillary and nodular tumor projected into the dilated intrahepatic bile duct (Fig. 4a). Microscopic examination showed papillary or tubular proliferation of atypical columnar or cuboidal cells in the dilated intrahepatic bile duct (Fig. 4b). Immunohistochemical patterns showed MUC1, MUC5AC, and MUC6 positive and MUC2 negative (Fig. 4c–f). These findings were similar to the first resection. From these findings, we diagnosed IPNB recurrence. Adjuvant chemotherapy was not re-administered on the basis of our judgment that curative resection has been achieved. The patient underwent follow-up CT examinations every 3 months for the first 2 years after the second surgery, and then underwent follow-ups every 6 months using CT and testing for serum tumor markers (CEA and CA19-9).

Forty-two months after the first resection, a 5-mm-sized frosted glass shadow was recognized in the right lung apex (Fig. 5a). In addition, we found a 5-mm-sized node from the left superior mediastinum to the ventral
pleura (Fig. 5b). Tumor markers did not increase, although we had followed up by taking chest CT scans every 4 months because we suspected inflammatory changes and/or tumor. The tumor on the right lung changed to a nodule and grew to 10 mm (Fig. 5c). We suspected lung metastasis or primary lung cancer; however, because the left lung node disappeared (Fig. 5d), we viewed it as inflammatory changes. Because of its increasing size, we strongly suspected malignant tumor (Fig. 5e, f). Serum tumor marker testing revealed elevated CEA (8.1 ng/mL) level but normal CA19-9 (33.5 U/mL) level, squamous cell carcinoma antigen (2.3 ng/mL), neuron-specific enolase (15.4 ng/mL), cytokeratin fragment (1.4 ng/mL), and pro-gastrin-releasing peptide (40.5 pg/mL). Brush cytology and biopsy on bronchoscopy revealed adenocarcinoma with negative thyroid transcription factor 1 (TTF-1) expression. From the cytohistologic features and clinical history, we presumed it to be lung metastasis from IPNB, resected in two separate procedures on the 54th month after the first resection. The size of both tumors had increased to 20 mm right before resection (Fig. 5g, h). Whole microscopic views showed nodular and cystic tumors in both tumors resected from the right and left lungs (Fig. 6a, h). A small daughter lesion near the main tumor was also noted in the left lung. Microscopically, both tumors showed papillary, tubular, or lepidic proliferation of atypical columnar cells (Fig. 6b, i). Immunohistochemistry revealed positive expression of MUC1, MUC5AC, and MUC6 but negative expression of MUC2 and TTF-1 (Fig. 6c–g, j–n) in both lung tumors. Although primary invasive mucinous carcinoma of the lung was a differential diagnosis, based on the similar histological features to previous IPNB, multiple tumor lesions in the lungs, imaging findings, and clinical history, we diagnosed it as pulmonary metastasis from IPNB. After both resections were completed, adjuvant chemotherapy was administered using tegafur (S-1) based on the recurrent lesions that we had detected. The S-1 regimen involved a dose of 120 mg/day for 4 consecutive weeks and then a 2-week break. The patient is currently alive (64 months after the first resection and 12 months after the lung resections), has completed four cycles of the S-1 regimen, and is continuing follow-up with monthly blood tests and CT evaluations every 3 months.

**Discussion and conclusion**

This case involved lung metastases from IPNB that developed after a liver recurrence and 54 months after resection of the primary IPNB. The diagnosis in this case was based on hematoxylin and eosin staining and immunohistochemical staining. To the best of our knowledge,
ours is only the third reported case of lung metastasis from IPNB, with the two other cases being described in a single-center survey by Höhn et al. [6] and in another case report [7]. TTF-1 is useful to distinguish primary lung adenocarcinoma from metastatic adenocarcinoma. TTF-1 is usually positive for primary lung adenocarcinoma but negative for adenocarcinoma of other organs [8]. However, differentiating primary invasive mucinous carcinoma of the lung from metastatic carcinoma of the bile duct or pancreas is challenging because both carcinomas show similar histological features (papillary and lepidic growth) and frequently negative TTF-1 expression [8]. In fact, the lung tumors in this case showed papillary and lepidic growth with negative TTF-1, although we diagnosed it as IPNB metastasis based on similar histological features to previous IPNB, multiple tumor lesions in the lungs, imaging findings, and the clinical history.

The IPNB subtype (gastric, intestinal, pancreatobiliary, or oncocytic) is often considered a counterpart to intraductal papillary mucinous neoplasms in the pancreas [9–11]. Immunohistochemistry can help to determine the immunophenotype, and our findings of positive MUC1 and MUC5AC expression supported a diagnosis of the pancreatobiliary type (Fig. 2). A previous report has indicated that “MUC5AC and MUC6 are frequently expressed by the gastric-type epithelium and MUC2 by the intestinal-type. MUC1 is frequently expressed by the pancreatobiliary-type epithelium and to a variable extent by the other epithelial types” [2]. Another report has also indicated that “a significantly higher proportion of pancreatobiliary compared with intestinal tumors expressed MUC1, whereas the reverse was the case of the MUC2 antigen that was expressed in the majority of intestinal tumors but seen only in frequently in pancreatobiliary tumors” [3]. In this context, when primary and metastatic specimens exhibit the same staining pattern, the diagnoses should also be the same. A recent report from a Japanese–Korean study group categorized IPNB into type 1 (intrahepatic) and type 2 (extrahepatic) [4], and this classification method was adopted by the WHO in 2019. Nevertheless, it remains unclear how to effectively classify the subtypes of IPNB, and MUC staining patterns may not be sufficient for diagnosing a specific subtype. However, these staining patterns are likely useful for confirming that the primary and metastatic specimens are related.

In the present case, the patient underwent resection of liver recurrence at 9 months after resection of the primary tumor. Furthermore, we were able to perform resection for both lung metastases at 48 months after the liver resection. We have continued to follow the patient, and the patient is alive and without evidence of recurrence at approximately 12 months after the lung resections. This case
suggests that resection may be effective for recurrence, given the patient’s long-term survival. Interestingly, the first resection had negative margins, although the patient still developed liver recurrence, which suggests that the IPNB was histologically present as a skip lesion in the preserved bile duct. The liver resection was also judged to be R0, although it is possible that the invasive component could have led to hematogenous spread, which is a possible explanation for the lung metastasis. In the CT image before the first resection, the tumor was localized in the S5. IPNB cases that produce mucus are mostly categorized as type 1, and invasive carcinoma is considered rare in comparison to type 2 [3, 12]. We doubted IPNB because mucus was grossly recognized, and images showed a papillary mass. It was difficult to determine it as benign tumor preoperatively, although we chose segmentectomy upon intraoperative diagnosis. We came across occasional reports that positron emission tomography (PET)-CT is useful in distinguishing benign and malignant in case of IPNB [12–14]. However, some argue that IPNB with small mural nodule and high amount of mucin may present as false negative [15]. In this case, we did not conduct fluorodeoxyglucose (FDG)-PET. If we had, we may have been able to determine that the first surgery should have been right hepatectomy. In addition, we had chosen a limited surgery because at the time we were not capable of operating peroral cholangioscopy or IDUS due to technical problems and because we considered IPNB a benign tumor. If we had chosen the first resection to be an extended surgery, we may have been able to prevent the hepatic relapse, and this is something we should reflect on. It is better to choose a surgery equivalent to that for a malignant tumor because it is hard to determine clear lesion localization of IPNB.

There was no clear justification for a preoperative diagnosis of lung metastasis from IPNB, which prompted us to perform bronchoscopic biopsy, and the immunostaining supported a diagnosis of IPNB metastasis and the decision to perform lung resection. The characteristics of the three reported cases with lung metastasis are summarized in Table 1. In all three cases, the initial resection was judged to be R0, and no adjuvant chemotherapy was administered. However, we treated our patient using adjuvant chemotherapy after the lung resections, based on his history of recurrence and metastasis. The two other reports did not describe the outcomes after resection of the lung metastases [6, 7], although both reports indicated that the diagnosis of metastasis was based on a comparison of the immunostaining results from the primary and lung specimens. Thus, the long-term outcomes of resection remain unclear, although our patient has achieved good survival to this point. Our patient also had a disease with an invasive component, which we suspect is associated with hematogenous spread, given the distant metastasis without lymph node involvement. In one of the previous cases, the preoperative suspicion was that the patient had lung cancer because non-invasive IPNB without lymph node metastasis is extremely rare; however, after the genomic analysis of the resected specimen, IPNB metastasis was confirmed. Thus, the authors suggested that the mechanism underlying metastasis is actually more complex than what was previously thought [7]. Performance status and age may be relevant when considering the resection of IPNB recurrence and/or metastasis; using appropriate surgical technique and careful case selection will not only allow better determination of long-term outcomes but also help to clarify the mechanism underlying metastasis by analysis of surgical specimens.

We are only aware of a few case reports regarding metastatic IPNB because it has a relatively benign course [7, 16]. Most of these reports have involved small retrospective studies, although Gordon-Weeks et al. reported a systematic review and meta-analysis in 2016 [2]. The results indicated that recurrence occurred in 13–29% of

| Case | Year | Author | First resected specimen | IPNB type | N | R | V | Immunosubtype | MUC 1 expression | Adjuvant therapy after first resection |
|------|------|--------|-------------------------|-----------|---|---|---|--------------|----------------|----------------------------------|
| 1    | 2019 | Höhn et al. [6] | pT2N0M0 invasive | 1          | 0 | 0 | 0 | Pancreatobiliary | Unknown | None |
| 2    | 2019 | Nam et al. [7] | pTisN0M0 non-invasive | 2          | 0 | 0 | 0 | Intestinal | Unknown | None |
| 3    | 2020 | Present case | pT2N0M0 invasive | 1          | 0 | 0 | 1 | Pancreatobiliary | Positive | None |

**Table 1** Reported cases of lung metastases from intraductal papillary neoplasm of the bile duct

IPNB intraductal papillary neoplasm of the bile duct, FOLFOX oxaliplatin, folic acid, and 5-fluorouracil, S-1 tegafur
cases after curative resection, and this proportion increased to 47–62% if the patient had invasive disease [17–19]. While the classification of IPNB remains complex, meta-analyses and multi-center cohort studies are gradually clarifying the outcomes and prognoses [2, 5, 6, 20, 21], and there is also increasing information regarding the surveillance protocols for IPNB and appropriate postoperative follow-up [5, 6, 22]. The present case involved an initial pathological diagnosis of invasive carcinoma with a MUC1-expressing pancreatobiliary type, which is a known prognostic factor. Based on the 2019 WHO classification, cholangiocarcinoma derived from IPNB has a 5-year recurrence rate of 47.0% and a 5-year overall survival rate of 68.8% [3]. In addition, the pancreatobiliary type has poorer clinical outcomes than the other subtypes, while MUC1 expression is associated with shorter recurrence-free survival [3]. Although IPNB is a slow-growing tumor, it has significant potential for progression to invasive disease, and Höhn et al. strongly suggested a short-interval follow-up even if benign IPNB has been completely resected [6]. In case of invasive IPNB, there is a good chance of expecting long-term survival by resection even if any lesion of recurrence/metastasis occurs. Therefore, we need to conduct a follow-up at short-term intervals, as suggested by Höhn et al. However, there is no clear difference in the treatment strategy for IPNB recurrence or metastasis, and further information is needed to determine whether these lesions need to be treated differently.

CT images showed different types of lung lesions (left and right). The lesion on the left lung decreased once its size, but showed growth afterwards, which confused our judgment. We followed up for nearly a year based on the acknowledgement that IPNB is a benign tumor but decided on resection upon recognition of the growth of the lung tumor. Generally, the lung is a minor site of recurrence in cholangiocarcinoma (CC), and chemotherapy is the first choice in case of intrahepatic CC lung metastasis. In CC, the lung metastasis rate after resection is reported to range from 1.6 to 11.7% [23–25]. In contrast, there are only a few reports in relation to IPNB metastasis. As for lung metastasis, reports by You et al. [5] reported one case (1.3%) of lung metastasis out of 74 cases of relapsed patients. IPNB has a better prognosis than conventional bile duct CC [26, 27]. Although IPNB has low malignancy (especially type 1), the rate of relapse in infiltrating cancer is around 47–62% [2, 3]. In case of a relapse or metastasis, systemic chemotherapy according to the biliary tract cancer is appropriate. Approved medication in Japan for the said cancer would be gemcitabine, tegafur, and cisplatin, of which a combination has not been established as an effective regimen in cases of adjuvant therapy for unresectable/relapsed biliary tract cancer. Beginning with BILCAP trials [28], there are several reports [29, 30] on the efficaciousness of chemotherapy for biliary tract cancer and recent reports on the efficaciousness of nab-paclitaxel [31]. Chemotherapy needs to be chosen properly, considering the performance status, age, and/or medical history of the patient. We expect further chemotherapy regimens for biliary tract cancer in the future. Because the disease concept of IPNB is relatively new, it is highly possible that something previously diagnosed as intrahepatic CC is now diagnosed as IPNB. We expect further collection of IPNB reports in the future.

In conclusion, we encountered a rare case of lung metastases from IPNB, which were diagnosed immunohisto logically. Given that IPNB is a slow-growing tumor, recurrence and/or metastasis may be detected during long-term follow-up. In case of invasive IPNB, there is a good chance of long-term survival by resection even if recurrence/metastasis occurs by conducting a follow-up at short-term intervals. It is also necessary to continue collecting information regarding the most effective techniques for managing these patients.

Abbreviations
CA19-9: Cancer antigen 19-9; CC: Cholangiocarcinoma; CEA: Carcinoembryonic antigen; CT: Computed tomography; ERC: Endoscopic retrograde cholangiography; IDUS: Intraductal ultrasonography; IPNB: Intraductal papillary neoplasm of the bile duct; SS: Segment 5; TTF-1: Thyroid transcription factor 1; WHO: World Health Organization

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Authors’ contributions
YM and RF designed the report, analyzed the data, and wrote the manuscript. RF, YM, TM, AN, and TN collected the patient’s clinical data. KH performed the pathological diagnosis and immunohistochemistry. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
The study was approved by the hospital’s review board of Tokai University School of Medicine (approval no: TOKAI 19R-026). Written informed consent was obtained from the patient.

Consent for publication
Written informed consent was obtained from the patient for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Surgery, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa 2591193, Japan. 2Department of Pathology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa 2591193, Japan.
Received: 14 May 2020 Accepted: 15 October 2020

References

1. Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001;34:651-8.

2. Gordon-Weeks AN, Jones K, Harriss E, Smith A, Silva M. Systematic review and meta-analysis of current experience in treating IPNB: clinical and pathological correlates. Ann Surg. 2016;263:566-63.

3. Nakamura Y, Bautrak O, Esposito J, Klimstra DS, Komuta M, Zen Y. Intraductal papillary neoplasm of the bile duct. In: WHO Classification of Tumors. Editorial Board. Digestive System Tumors WHO Classification of Tumors. 5th ed: World Health Organization; 2019. p. 279-82.

4. You Y, Choi SH, Choi DW, Heo JS, Han IW, Jang KT, et al. Recurrence after resection for intraductal papillary neoplasm of the bile duct (IPNB) according to tumor location. J Gastrointest Surg. 2019;23:804-12.

5. Höhn P, Braumann C, Munding J, Tannapfel A, Uhl W, Künzli BM. Outcome determining factors of intraductal papillary neoplasm of the biliary tract (IPNB)-a single center survey and analysis of current literature. J Gastrointest Cancer. 2019;50:160-9.

6. Nam NH, Taura K, Kanai M, Fukuyama K, Uza N, Maeda H, et al. Unexpected metastasis of intraductal papillary neoplasm of the bile duct without an invasive component to the brain and lungs: a case report. World J Gastroenterol. 2020;26:366-74.

7. Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Long-term growth of intrahepatic papillary neoplasms: a case report. World J Gastroenterol. 2019;25:5569-77.

8. Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival. World J Surg. 2017;41:1550-7.

9. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651-8.

10. Yedibelis S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönenfeld F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol. 2009;16:404-12.

11. Jamagin WR, Bowone W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241:703-12 discussion 712-4.

12. Tajima Y, Kuroki T, Fukuda K, Tsunekawa N, Furuj C, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg. 2004;91:99-104. https://doi.org/10.1002/bjs.4366.

13. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicenter, phase 3 study. Lancet Oncol. 2019;20:663-73.

14. Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2019;98:e14013.

15. Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, et al. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci. 2014;21:176-85.

16. Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fuji H, et al. Usefulness of preoperative 18-FDG-PET in detecting invasive intraductal papillary neoplasm of the bile duct. Anticancer Res. 2019;39:4569-73.

17. Kubota K, Nakanuma Y, Kondo F, Hachiya H, Miyazaki M, Nagino M, et al. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci. 2014;21:176-85.

18. Sato T, Hitaka S, Sakai H, Ishikawa H, Kawaihara R, Goto Y, et al. Clinicopathological study of resections of intraductal papillary neoplasm of the bile duct. Hepatogastrentroenterol. 2011;58:404-6.

19. Kinoshita M, Takemura S, Tanaka S, Shinkawa H, Hamano G, Itou T, et al. The clinical significance of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with occupational cholangiocarcinoma. Asian Pac J Cancer Prev. 2018;19:1753-9.

20. Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fujii H, et al. Long-term growth of intrahepatic papillary neoplasms of the bile duct. Ann Nucl Med. 2012;26:594-8.

21. Yoshida Y, Aiki T, Ueno K, Ohtsubo I, Murakami S, Shinozaki K. Advanced intraductal papillary neoplasm of bile duct (IPNB) in a young female with metastases to lymph nodes and ovary. Tando. 2012;26:231-6.

22. Rocha FG, Lee H, Katabi N, DeMatteo RP, Fong Y, D’Angelica MI, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012;56:1352-60.

23. Tsuyuguchi T, Saiki Y, Sugiyama H, Miyakawa K, Ishihara T, Ohtsuka M, et al. Endoscopic diagnosis of intraductal papillary mucinous neoplasm of the bile duct. J Hepatobiliary Pancreat Sci. 2010;17:230-5.

24. D’Souza MA, Isaksson B, Löhr M, Enochsson L, Swahn F, Lundell L, et al. The clinicopathological spectrum and management of intraductal papillary mucinous neoplasm of the bile duct (IPMN-B). Scand J Gastroenterol. 2013;48:473-9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.